Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2010 1
2014 1
2015 3
2016 3
2017 2
2018 1
2019 2
2020 5
2021 1
2022 8
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K. Mitsuoka S, et al. Among authors: yoshimoto n. Expert Opin Pharmacother. 2016;17(2):193-203. doi: 10.1517/14656566.2016.1109635. Epub 2016 Jan 18. Expert Opin Pharmacother. 2016. PMID: 26781399 Review.
Acromegaly Initially Presenting with Severe Infectious Diseases: A Case Report.
Tani E, Hirashima T, Hasegawa T, Aohara D, Oshima Y, Sakurai Y, Hirai K, Yoshimoto N, Nishida M, Tateishi Y, Minami K. Tani E, et al. Among authors: yoshimoto n. JMA J. 2022 Jan 17;5(1):161-166. doi: 10.31662/jmaj.2021-0150. Epub 2021 Dec 24. JMA J. 2022. PMID: 35224284 Free PMC article.
Vascular endothelial growth factor receptor 2 expression and immunotherapy efficacy in non-small cell lung cancer.
Nakahama K, Kaneda H, Osawa M, Fukui M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: yoshimoto n. Cancer Sci. 2022 Sep;113(9):3148-3160. doi: 10.1111/cas.15464. Epub 2022 Jul 18. Cancer Sci. 2022. PMID: 35722982 Free PMC article.
Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K, Kaneda H, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: yoshimoto n. Thorac Cancer. 2022 Aug;13(16):2309-2317. doi: 10.1111/1759-7714.14560. Epub 2022 Jul 8. Thorac Cancer. 2022. PMID: 35808895 Free PMC article.
SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3.
Nakahama K, Osawa M, Izumi M, Yoshimoto N, Sugimoto A, Nagamine H, Ogawa K, Matsumoto Y, Sawa K, Tani Y, Kaneda H, Mitsuoka S, Watanabe T, Asai K, Kawaguchi T. Nakahama K, et al. Among authors: yoshimoto n. Transl Lung Cancer Res. 2022 Dec;11(12):2438-2451. doi: 10.21037/tlcr-22-496. Transl Lung Cancer Res. 2022. PMID: 36636414 Free PMC article.
31 results